BR9916735A - 3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy - Google Patents

3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Info

Publication number
BR9916735A
BR9916735A BR9916735-2A BR9916735A BR9916735A BR 9916735 A BR9916735 A BR 9916735A BR 9916735 A BR9916735 A BR 9916735A BR 9916735 A BR9916735 A BR 9916735A
Authority
BR
Brazil
Prior art keywords
heteroarylidenyl
protein kinase
cancer chemotherapy
indolinone compounds
kinase activity
Prior art date
Application number
BR9916735-2A
Other languages
Portuguese (pt)
Inventor
Peter J Langecker
Laura Kay Shawver
Peng Cho Tang
Li Sun
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of BR9916735A publication Critical patent/BR9916735A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>''COMPOSTOS DE 3-HETEROARILIDENIL-2-INDOLINONA PARA A MODULAçãO DA ATIVIDADE DAS CINASES PROTéICAS E PARA USO NA QUIMIOTERAPIA DO CâNCER''<D>. A presente invenção refere-se aos compostos de 3-heteroarilidenil-2-indolinona que modulam a atividade de cinases protéicas e, portanto, são esperados ser úteis na prevenção e no tratamento de distúrbios celulares relacionados à cinase protéica, tais como o câncer. Além disso, estes compostos são esperados aumentar a eficácia de outros agentes quimioterapêuticos, em particular, as pirimidinas fluoradas, no tratamento de câncer.Invention Patent: <B> '' 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING THE ACTIVITY OF PROTEIN KINASES AND FOR USE IN CANCER CHEMOTHERAPY '' <D>. The present invention relates to the 3-heteroarylidenyl-2-indolinone compounds that modulate the activity of protein kinases and, therefore, are expected to be useful in the prevention and treatment of cell disorders related to protein kinase, such as cancer. In addition, these compounds are expected to increase the effectiveness of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.

BR9916735-2A 1998-12-31 1999-12-30 3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy BR9916735A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11431398P 1998-12-31 1998-12-31
PCT/US1999/031232 WO2000038519A1 (en) 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Publications (1)

Publication Number Publication Date
BR9916735A true BR9916735A (en) 2001-09-25

Family

ID=22354480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916735-2A BR9916735A (en) 1998-12-31 1999-12-30 3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Country Status (10)

Country Link
EP (1) EP1139754A4 (en)
JP (1) JP2002533360A (en)
KR (1) KR20010108063A (en)
CN (1) CN1356872A (en)
AU (1) AU760964B2 (en)
BR (1) BR9916735A (en)
CA (1) CA2357042A1 (en)
IL (1) IL143920A0 (en)
MX (1) MXPA01006742A (en)
WO (1) WO2000038519A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
DK1233943T3 (en) * 1999-11-24 2011-08-15 Sugen Inc Ionizable indolinone derivatives and their use as PTK ligands
EA005996B1 (en) * 2000-02-15 2005-08-25 Сьюджен, Инк. Pyrrole substituted 2-indolinone, pharmaceutical composition, method of modulating catalytic activity of protein kinase, method of prevention and treatment of disorders related to protein kinase
CZ298259B6 (en) * 2000-02-28 2007-08-08 Aventis Pharma S. A. Pharmaceutical combinations containing CPT-11 and capecitabine for treating cancer
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AR038957A1 (en) * 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
WO2003035619A1 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003035616A2 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002348393A1 (en) * 2001-10-25 2003-05-06 Merck And Co., Inc. Tyrosine kinase inhibitors
CA2466807A1 (en) * 2001-11-21 2003-06-05 Sugen, Inc. Pharmaceutical formulations comprising indolinone derivatives
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002360753B2 (en) 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
MXPA04012418A (en) 2002-06-25 2005-04-19 Wyeth Corp Use of thio-oxindole derivatives in treatment of skin disorders.
BR0312054A (en) 2002-06-25 2005-10-18 Wyeth Corp Use of thiooxyindole derivatives in the preparation of medicaments useful in the treatment of hormone related conditions, and pharmaceutical kit
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CN100491374C (en) 2002-08-02 2009-05-27 Ab科学公司 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors
CA2506085A1 (en) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
US7718676B2 (en) 2003-10-23 2010-05-18 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
CN100432071C (en) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 Substituted 1H-indole-2-ketone compound and its preparation method and uses
EP2361624A1 (en) 2005-04-04 2011-08-31 AB Science Oxazole derivatives and their use as tyrosine kinase inhibitors
US8246966B2 (en) 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
CA2669531A1 (en) 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
HUE037928T2 (en) * 2011-11-11 2018-09-28 Lilly Co Eli Combination therapy for ovarian cancer
JP7041515B2 (en) 2015-01-08 2022-03-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Factors and cells that provide bone, bone marrow, and cartilage induction
EP3288940B9 (en) 2015-04-29 2021-07-21 Janssen Pharmaceutica NV Azabenzimidazoles and their use as ampa receptor modulators
CN105585558A (en) * 2015-12-15 2016-05-18 贵州大学 Double-alkoxy pyrimidine jointing 3-ethylenic-bond-oxoindole derivative and preparing method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Also Published As

Publication number Publication date
WO2000038519A1 (en) 2000-07-06
EP1139754A1 (en) 2001-10-10
CN1356872A (en) 2002-07-03
EP1139754A4 (en) 2002-12-18
AU760964B2 (en) 2003-05-22
CA2357042A1 (en) 2000-07-06
AU2221500A (en) 2000-07-31
KR20010108063A (en) 2001-12-07
MXPA01006742A (en) 2004-04-21
JP2002533360A (en) 2002-10-08
IL143920A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
BR9916735A (en) 3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
PA8515701A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS TO INHIBIT PROTEIN KINASES
PT1017384E (en) COMPOUNDS BASED ON AZABENZIMIDAZOLE FOR MODULATION OF THE FUNCTION OF A SERINE / TREONINE PROTEIN KINASE
BR9814814A (en) Processes for modulating serine / threonine protein kinase function with 5-azaquinoxaline-based compounds
BR9915210A (en) N-aryl-amides of anthranilic acid-and thioanthranilic acid
BRPI0007487B8 (en) diphenyl-ureas substituted with w-carboxy-aryls as raf kinase inhibitors
BR0007527A (en) Phenylphenanthridines with IV-dependent inhibitory activity
EP0984930A4 (en) 2-indolinone derivatives as modulators of protein kinase activity
CR20120009A (en) 2-INDOLINONES REPLACED WITH PROTEINQUINASE INHIBITING PIRROLS (DIVISIONAL EXP. 6728)
BR0308339A (en) Indazoles Replaced with Anticancer Activity
BR9713338A (en) Benzonaphyridines as bronchial therapeutics.
WO2000008202A3 (en) 3-methylidenyl-2-indolinone modulators of protein kinase
BR0008447A (en) Methods of treating mitochondrial disorders
BR0107643A (en) Compositions and processes for prostate cancer therapy and diagnosis
BR9811956A (en) Naphthyridinones for the inhibition of protein tyrosine kinase and cell cycle kinase-mediated cell proliferation
TR200001312T2 (en) Benzothiazole protein tyrosine kinase inhibitors.
BR9806752A (en) Phthalazinones.
BR9805544A (en) Use of a compound.
BR0013081A (en) Metalloproteinase-inhibiting pyrimidine-2,4,6-triones
BR9808697A (en) Process to inhibit the growth of a tumor, defective adenovirus vector, virus vector, use of it, and pharmaceutical composition
DE69905170T2 (en) THIAZOLOPYRIMIDINDERIVATE
BRPI0408477A (en) phosphate / sulfate ester compounds and pharmaceutical compositions for inhibiting the use of protein (pin 1) and their use
AR020563A1 (en) TIA-ALQUINOIC COMPOUNDS (POLI) AND THEIR DERIVATIVES, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE
SV1999000204A (en) DERIVATIVES OF INDOL REF. PCS10311AKSR / BB
GT199800081A (en) FARNESIL TRANSFERASA INHIBITORS COMBINED WITH HMG COA REDUCTASE INHIBITORS FOR DELCANCER TREATMENT.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.